Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125505682 | 12550568 | 2 | F | 2016 | 20160816 | 20160712 | 20160822 | PER | US-PFIZER INC-2016320922 | PFIZER | 55.00 | YR | F | Y | 95.25000 | KG | 20160822 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125505682 | 12550568 | 1 | PS | EFFEXOR XR | VENLAFAXINE HYDROCHLORIDE | 1 | Oral | 75 MG, UNK | U | 20699 | 75 | MG | PROLONGED-RELEASE CAPSULE | ||||||
| 125505682 | 12550568 | 2 | SS | EFFEXOR XR | VENLAFAXINE HYDROCHLORIDE | 1 | Oral | 225 MG, 1X/DAY | U | 20699 | 225 | MG | PROLONGED-RELEASE CAPSULE | QD | |||||
| 125505682 | 12550568 | 3 | SS | EFFEXOR XR | VENLAFAXINE HYDROCHLORIDE | 1 | Oral | 75 MG, UNK | U | 20699 | 75 | MG | PROLONGED-RELEASE CAPSULE | ||||||
| 125505682 | 12550568 | 4 | SS | EFFEXOR XR | VENLAFAXINE HYDROCHLORIDE | 1 | Oral | 150 MG, 1X/DAY | U | M76000 | 20699 | 150 | MG | PROLONGED-RELEASE CAPSULE | QD | ||||
| 125505682 | 12550568 | 5 | C | KLONOPIN | CLONAZEPAM | 1 | 2 MG, 2X/DAY | 0 | 2 | MG | BID | ||||||||
| 125505682 | 12550568 | 6 | C | SEROQUEL | QUETIAPINE FUMARATE | 1 | 500 MG, 1X/DAY (AT NIGHT) | 0 | 500 | MG | QD | ||||||||
| 125505682 | 12550568 | 7 | C | REQUIP | ROPINIROLE HYDROCHLORIDE | 1 | 4 MG, 1X/DAY (AT NIGHT) | 0 | 4 | MG | QD | ||||||||
| 125505682 | 12550568 | 8 | C | ROBAXIN | METHOCARBAMOL | 1 | 750 MG, 3X/DAY | 0 | 750 | MG | TID | ||||||||
| 125505682 | 12550568 | 9 | C | NEURONTIN | GABAPENTIN | 1 | 600 MG, 4X/DAY | 0 | 600 | MG | QID | ||||||||
| 125505682 | 12550568 | 10 | C | NEURONTIN | GABAPENTIN | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125505682 | 12550568 | 1 | Depression |
| 125505682 | 12550568 | 2 | Anxiety |
| 125505682 | 12550568 | 6 | Sleep disorder |
| 125505682 | 12550568 | 7 | Restless legs syndrome |
| 125505682 | 12550568 | 8 | Fibromyalgia |
| 125505682 | 12550568 | 9 | Depression |
| 125505682 | 12550568 | 10 | Anxiety |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125505682 | 12550568 | Agitation | |
| 125505682 | 12550568 | Feeling abnormal | |
| 125505682 | 12550568 | Insomnia | |
| 125505682 | 12550568 | Memory impairment | |
| 125505682 | 12550568 | Post-traumatic stress disorder | |
| 125505682 | 12550568 | Withdrawal syndrome |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125505682 | 12550568 | 2 | 201606 | 0 |